2024-519301-36-00招募中1 期
A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.3 个研究点 分布在 2 个国家目标入组 40 人开始时间: 2025年6月18日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by DabigatranHemorrhageNCT01955720Boehringer Ingelheim46
已完成
2 期
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar PustulosisPalmoplantar Pustulosis (PPP)NCT04015518Boehringer Ingelheim152
已完成
2 期
Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of SeasonRhinitis, Allergic, SeasonalAsthmaNCT01007721Boehringer Ingelheim146
已完成
1 期
Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or AutoinjectorHealthyNCT02606903Boehringer Ingelheim71
已完成
1 期
A Study to Test Different Doses of BI 456906 in Patients With ObesityObesityNCT03591718Boehringer Ingelheim131